

Datasheet for 100-4167C**IKB alpha Antibody****Overview**

Description:	Anti-IKB α C-terminal (RABBIT) Antibody - 100-4167C
Item No.:	100-4167C
Size:	100 μ L
Applications:	WB, EMSA
Reactivity:	Human, Mouse, Rat
Host Species:	Rabbit

Product Details

Background:	Anti-IKB alpha Antibody detects Ikb α . I-kappa-B-alpha inhibits the activity of dimeric NF-kappa-B/REL complexes by trapping REL dimers in the cytoplasm through masking of their nuclear localization signals. On cellular stimulation by immune and proinflammatory responses, IKBA becomes phosphorylated promoting ubiquitination and degradation, enabling the dimeric RELA to translocate to the nucleus and activate transcription. Anti-IKB α Antibody is ideal for investigators involved in Cell Signaling, Neuroscience, Signal Transduction and Immunology research.
Synonyms:	rabbit anti-IKB alpha Antibody, IkappaBalphabet antibody, IKBA antibody, IKBalpha antibody, MAD3 antibody, NF kappa B inhibitor alpha antibody, NFKBI antibody, NFKBIA antibody
Host Species:	Rabbit
Clonality:	Polyclonal
Format:	Antiserum

Target Details

Gene Name:	NFKBIA
Reactivity:	Human, Mouse, Rat
Immunogen Type:	Conjugated Peptide
Immunogen:	IKB alpha Antibody was produced by repeated immunizations with a synthetic Ikb α peptide corresponding to a region near the C-terminus of the human protein.

Purity/Specificity:	IkB alpha Antibody was prepared from monospecific antiserum by delipidation and defibrination. Anti- IkBa may react non-specifically with other proteins. Control peptide (code #100-4167P) will compete only with the specific reaction of antiserum with IkBa.
Relevant Links:	• NCBI - CAB65556.2 • UniProtKB - P25963 • GeneID - 4792

Application Details


Tested Applications:	WB
Suggested Applications:	EMSA (Based on references)
Application Note:	Anti-IkBα Antibody has been tested by western blot and is suitable for ELISA, and IHC. Researchers should determine optimal titers for applications that are not stated below.
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.
ELISA:	1:20,000 - 1:100,000
IHC:	1:1,000 - 1:5,000
WB:	1:2,000 - 1:10,000

Formulation

Physical State:	Liquid (sterile filtered)
Concentration:	80 mg/mL by Refractometry
Buffer:	0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Preservative:	0.1% (w/v) Sodium Azide
Stabilizer:	None

Shipping & Handling

Shipping Condition:	Dry Ice
Storage Condition:	Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.



Western Blot

Western Blot of Rabbit anti-IKB α C-terminal antibody. Lane 1: IKB α C-terminal. Load: 50 ng per lane. Primary antibody: IKB α C-terminal antibody at 1:500 for overnight at 4°C. Secondary antibody: Peroxidase rabbit secondary antibody at 1:40,000 for 30 min at RT. Block: Blocking Buffer for Fluorescent Western Blotting (MB-070) for 30 min RT. Predicted/Observed size: 61 kDa, 61 kDa for IKB α C-terminal.

References

- Wan YY et al. The survival of antigen-stimulated T cells requires NF κ B-mediated inhibition of p73 expression. *Immunity*. (2003)
- Cheshire JL et al. Involvement of Double-stranded RNA-activated Protein Kinase in the Synergistic Activation of Nuclear Factor- κ B by Tumor Necrosis Factor- α and γ -Interferon in Preneuronal Cells. *J Biol Chem*. (1999)
- Miller WE et al. Interaction of tumor necrosis factor receptor-associated factor signaling proteins with the latent membrane protein 1 PXQXT motif is essential for induction of epidermal growth factor receptor expression *Mol Cell Biol* (1998)
- Cheshire JL et al. Synergistic activation of NF-kappaB by tumor necrosis factor alpha and gamma interferon via enhanced I kappaB alpha degradation and de novo I kappaBbeta. *Mol Cell Biol* (1997)

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.